Appendix Table 4.

Hazard ratios (95% confidence intervals) of coronary heart disease for continuous use of estrogen-plus-progestin therapy versus no hormone therapy use with a different distribution and transformation of hormone use, the Women's Health Initiative randomized trial

	Follow-up period
	Overall (8-year cumulative use)	≤2 years (2-year cumulative use)	>2 years (6-year cumulative use)
All women
Gamma distribution	1.66 (0.96, 2.89)	2.33 (1.53, 3.56)	1.31 (0.86, 2.00)
Arcsin-root transformation	1.91 (1.05, 3.48)	2.66 (1.67, 4.23)	1.44 (0.91, 2.27)
Years since menopause
< 10
Gamma distribution	0.69 (0.22, 2.16)	1.20 (0.49, 2.97)	0.67 (0.28, 1.61)
Arcsin-root transformation	0.70 (0.22, 2.28)	1.40 (0.52, 3.75)	0.67 (0.27, 1.66)
≥ 10
Gamma distribution	2.16 (1.14, 4.08)	2.84 (1.75, 4.61)	1.60 (0.97, 2.63)
Arcsin-root transformation	2.55 (1.28, 5.11)	3.26 (1.90, 5.61)	1.80 (1.04, 3.10)
Age at baseline (years)
50-59
Gamma distribution	1.48 (0.58, 3.80)	2.50 (1.06, 5.93)	1.23 (0.59, 2.55)
Arcsin-root transformation	1.76 (0.62, 4.95)	3.09 (1.19, 8.02)	1.39 (0.62, 3.12)
≥ 60
Gamma distribution	1.72 (0.93, 3.18)	2.30 (1.43, 3.70)	1.34 (0.83, 2.15)
Arcsin-root transformation	1.96 (1.01, 3.81)	2.57 (1.52, 4.34)	1.46 (0.88, 2.42)